It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Evaluating the value of travel points against cash back can impact your rewards strategy. Discover which option offers the greatest benefits for your needs.
26,201 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
In 2026, Part B premiums surged to $202.90 as Social Security COLA lagged, highlighting medicare premium growth often...
Could XRP slip below $2 by 2027? This guide breaks down the three big hurdles, explains why a lower price is plausibl...
Circle announces a $222 million Arc token presale at a $3 billion FDV, drawing major investors as quarterly revenue g...
A spotlight on KNG shows it earns an 8.6% yield by selling covered calls on Dividend Aristocrats, but eight-year retu...
When a company executive moves tens of thousands of shares, it sparks questions. This guide explains what insider sel...
As Apple prepares for a leadership transition, the company emphasizes AI as a tool to strengthen products, not a stan...
Boise remains a retirement magnet, but costs have risen. With a $900K pot, a paid-off home, and careful tax and cash-...
Bitcoin’s mining difficulty jumped about 15% to roughly 144T, signaling a rapid shift in miner economics. Early on-ch...
Nvidia CEO Jensen Huang laid out a striking forecast where AI agents work alongside a much larger human workforce, re...
Canadian traders face a fast-moving market in May 2026 as platforms race to lower costs and boost real-time data. Thi...
Yields on the 10-year Treasury push toward a key 4.75% level as investors weigh dividend-growth strategies against hi...